TLSIW — TriSalus Life Sciences, Inc.
—
Nasdaq ·
Health Care ·
Health Care Equipment & Supplies ·
CIK 1826667 ·
Last close
—
Market Cap
—
52W High
—
52W Low
—
ADV30
—
Next earnings
—
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | GrossProfit | OpIncome | NetIncome | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Mar 2026 | 8,899,000 | 7,669,000 | -8,411,000 | 1,539,000 | 70,979,000 | 56,553,000 | 58,172,000 |
| Dec 2025 | 13,205,000 | 11,443,000 | -3,271,000 | -9,753,000 | 35,331,000 | 20,439,000 | 69,192,000 |
| Sep 2025 | 11,566,000 | 9,660,000 | -9,014,000 | -10,811,000 | 36,463,000 | 22,687,000 | 63,188,000 |
| Jun 2025 | 11,213,000 | 9,411,000 | -7,332,000 | -8,288,000 | 41,317,000 | 26,490,000 | 60,740,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-18,012,000
Investing CF
$-838,000
Financing CF
$30,764,000
CapEx
$-1,061,000
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
—
As of
2026-05-10
Balance + Analyst (yfinance extras)
Retained Earnings
$-330,583,000
Inventory
$3,077,000
Receivables
$6,558,000
ST Investments
—
EBIT TTM
$-33,676,000
Pretax Income TTM
$-39,220,000
Interest Exp TTM
$5,544,000
Analysts
—
Yahoo Snapshot (yfinance, live)
Total Revenue
$44,883,000
EBITDA
$-27,439,000
Free Cash Flow
$-9,303,375
Enterprise Value
—
Total Cash
$56,553,000
Total Debt
$34,487,000
Shares Out
—
Trailing EPS
—
Book Value
$-0.68
ROE
—
ROA
-35.2%
Div Yield
—
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | OpIncome | NetIncome | Assets | Liabilities | Equity | OCF |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 45,151,000 | -26,946,000 | -39,227,000 | 35,331,000 | 69,192,000 | — | -18,012,000 |
| Dec 2024 | 29,431,000 | -36,165,000 | -30,045,000 | 23,971,000 | 49,865,000 | — | -40,843,000 |
| Dec 2023 | 18,511,000 | -54,475,000 | -59,363,000 | 24,598,000 | 51,663,000 | — | -50,578,000 |
| Dec 2022 | 12,398,000 | -36,439,000 | -47,187,000 | 21,995,000 | 198,325,000 | — | -32,313,000 |
TTM Snapshot
Revenues TTM
$16,480,000
NetIncome TTM
$-13,850,000
OpCashFlow TTM
$0
Assets (Latest)
$23,971,000
Forward EPS
—
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| ISRG | INTUITIVE SURGICAL INC | $154.64B | $436.64 | — |
| SYK | STRYKER CORP | $119.99B | $313.00 | — |
| MDT | Medtronic plc | $99.63B | $77.60 | — |
| BSX | BOSTON SCIENTIFIC CORP | $85.67B | $57.64 | — |
| MMM | 3M CO | $80.34B | $154.03 | — |
News headlines (Yahoo Finance, 1h cache)
TriSalus Life Sciences Inc (TLSI) Q1 2026 Earnings Call Highlights: Strategic Expansion and ...
2026-05-13 05:01 · Yahoo
TriSalus Life Sciences Q1 Earnings Call Highlights
2026-05-13 02:06 · Yahoo
TriSalus Life Sciences, Inc. Q1 2026 Earnings Call Summary
2026-05-13 00:47 · Yahoo
TriSalus Life Sciences, Inc. (TLSI) Reports Q1 Loss, Lags Revenue Estimates
2026-05-12 21:15 · Yahoo
TriSalus (TLSI) Initiates Patient Enrollment for PREDICTT Liver Tumor Clinical Trial
2026-05-10 04:01 · Yahoo
TriSalus Life Sciences Announces Launch of PREDICTT Clinical Trial Evaluating Pressure-Enabled Drug Delivery in Liver Tumors
2026-05-04 21:24 · Yahoo
TriSalus Life Sciences to Host First Quarter 2026 Financial Results Conference Call
2026-04-28 20:05 · Yahoo
TriSalus Life Sciences to Present New Data at the 2026 Society of Interventional Radiology Annual Scientific Meeting
2026-04-09 20:05 · Yahoo
TriSalus Life Sciences Appoints Richard Marshall, M.D., as Chief Medical Officer
2026-04-07 13:15 · Yahoo
TriSalus Life Sciences Announces Publication Demonstrating Enhanced Delivery and Immune Activation with Nelitolimod Delivered with Pressure-Enabled Drug Delivery in Liver Tumor Models
2026-03-18 12:00 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.